Actavis Inc. is conducting a Phase 3 clinical trial to establish the therapeutic equivalence of its generic ingenol mebutate gel (0.05%) against the branded Picato gel (0.05%) for the treatment of actinic keratosis (AK). The successful outcome of this trial could position Actavis favorably in the dermatological market, particularly as the patent for Picato is likely to expire, allowing for increased competition in the AK treatment space. The market for AK treatments is significant, with a growing prevalence of skin conditions due to aging populations and increased sun exposure. The trial's completion and positive results could enhance Actavis's portfolio and market share in dermatology, while also presenting potential cost-saving options for patients and healthcare systems.